Secondary analysis of the phase 3 ARASENS trial in 472 European patients with metastatic hormone-sensitive prostate cancer: darolutamide plus ADT and docetaxel vs placebo reduced risk of death (HR 0.63); serious adverse events 37.9% vs 43.1%.
Secondary analysisn = 472
Tombal et al. Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial